NASDAQ:MOR - Nasdaq - US6177602025 - ADR - Currency: USD
18.96
+0.45 (+2.43%)
The current stock price of MOR is 18.96 USD. In the past month the price increased by 1.94%. In the past year, price increased by 144.65%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
MorphoSys AG
Semmelweisstr. 7
Planegg BAYERN 82152 DE
CEO: Jean-Paul Kress
Employees: 464
Company Website: https://www.morphosys.com
Phone: 4989899270
The current stock price of MOR is 18.96 USD. The price increased by 2.43% in the last trading session.
The exchange symbol of MorphoSys AG is MOR and it is listed on the Nasdaq exchange.
MOR stock is listed on the Nasdaq exchange.
12 analysts have analysed MOR and the average price target is 5.06 USD. This implies a price decrease of -73.33% is expected in the next year compared to the current price of 18.96. Check the MorphoSys AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MorphoSys AG (MOR) has a market capitalization of 2.86B USD. This makes MOR a Mid Cap stock.
MorphoSys AG (MOR) currently has 464 employees.
MorphoSys AG (MOR) has a support level at 18.58 and a resistance level at 19. Check the full technical report for a detailed analysis of MOR support and resistance levels.
The Revenue of MorphoSys AG (MOR) is expected to decline by -3.33% in the next year. Check the estimates tab for more information on the MOR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MOR does not pay a dividend.
MorphoSys AG (MOR) will report earnings on 2024-08-29, after the market close.
MorphoSys AG (MOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.38).
ChartMill assigns a technical rating of 9 / 10 to MOR. When comparing the yearly performance of all stocks, MOR is one of the better performing stocks in the market, outperforming 98.16% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to MOR. MOR has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months MOR reported a non-GAAP Earnings per Share(EPS) of -3.38. The EPS decreased by -160.42% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -25.13% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 70% to MOR. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 20.86% and a revenue growth -3.33% for MOR